PET — staging/diagnosis
| Item | Description |
| 61523 | Whole body FDG PET study, performed for evaluation of a solitary pulmonary nodule where the lesion is considered unsuitable for transthoracic fine needle aspiration biopsy, or for which an attempt at pathological characterisation has failed. |
| 61524 | Whole body 18F-FDG PET study where the patient is referred by a specialist or consultant physician, performed for the staging of locally advanced (Stage III) breast cancer in a patient considered potentially suitable for active therapy |
| 61529 | Whole body FDG PET study, performed for the staging of proven non-small cell lung cancer, where curative surgery or radiotherapy is planned. |
| 61553 | Whole body FDG PET study, following the initial therapy, performed for the evaluation of suspected metastatic or recurrent malignant melanoma in patients considered suitable for active therapy. |
| 61559 | FDG PET study of the brain, performed for the evaluation of refractory epilepsy which is being evaluated for surgery. |
| 61560 | FDG PET study of the brain, performed for the diagnosis of Alzheimer's Disease (patient cannot have had a PET or NM Brain Scan within last 12months). Applicable not more than 3 times per lifetime |
| 61563 | Whole body PSMA PET study for initial staging of intermediate - high risk prostate adenocarcinoma for a previously untreated patient who is considered suitable for locoregional therapy with curative intent. Applicable once per lifetime |
| 61571 | Whole body FDG PET study, for the further primary staging of patients with histologically proven carcinoma of the uterine cervix, at FIGO stage IB2 or greater by conventional staging, prior to planned radical radiation therapy or combined modality therapy with curative intent. |
| 61577 | Whole body FDG PET study, performed for the staging of proven oesophageal or GEJ carcinoma, in patients considered suitable for active therapy. |
| 61598 | Whole body FDG PET study performed for the staging of biopsy-proven newly diagnosed or recurrent head and neck cancer. |
| 61610 | Whole body FDG PET study performed for the evaluation of metastatic squamous cell carcinoma of unknown primary site involving cercical nodes. |
| 61612 | Whole body FDG PET study for the initial staging of eligible cancer types, for a patient who is considered suitable for active therapy, if: (a) the eligible cancer type is: (i) a rare or uncommon cancer (less than 12 cases per 100,000 persons per year); and (ii) a typically FDG‑avid cancer; and (b) there is at least a 10% likelihood that the PET study result will inform a significant change in management for the patient Applicable once per cancer diagnosis (R) |
| 61620 | Whole body FDG PET study for the initial staging of newly diagnosed or previously untreated Hodgkin's or non-Hodgkin's lymphoma (excluding indolent non-Hodgkin's lymphoma). |
| 61640 | Whole body FDG PET study for initial staging of patients with biopsy-proven bone or soft tissue sarcoma (excluding gastrointestinal stromal tumour) considered by conventional staging to be potentially curable. |